The Queen Mary University of London professor leading an international breast cancer study says anastrozole -- rather than tamoxifen -- should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
IBIS-II study finds anastrozole reduces breast cancer rates for high risk postmenopausal women
- EurekAlert
- 12. 12 2019 (06:00)